Document is current
Any future updates will be listed below
-
Authors
Xiao, Y.
Hu, X.
Rudolphi, C. F.
Nollet, E. E.
Nederlof, R.
Wang, Q.
Bakker, D.
Nikolaou, Panagiota Efstathia
Knol, J. C.
Haas, R. R. Goeij-de
Henneman, A. A.
Pham, T. V.
Jimenez, C. R.
Grootemaat, A. E.
van der Wel, N. N.
Girardin, S. E.
Kaludercic, N.
van der Velden, J.
Onódi, Z.
Leszek, P.
Varga, Z. V.
Ferdinandy, P.
Preckel, B.
Weber, N. C.
Hollmann, M. W.
Di Lisa, F.
Zuurbier, C. J. https://orcid.org/0000-0001-8361-2448
-
Funding
Funding for this research was provided by:
NWO (91818602)
Heinrich-Heine-Universität Düsseldorf
NWO-ZonMW (91818602)
Dutch Cardiovascular Alliance (2021)
Fondation Leducq (20CVD01)
Fondation Leducq (16cvd04)
HORIZON EUROPE European Innovation Council (739593)
HORIZON EUROPE European Innovation Council (739593)
New National ExcellenceProgrm of the Ministry of Human Capacities (unkp-22-4-ii-se-3)
ZON-MW (2021/38315/ZONMW)
Horizon 2020 Framework Programme (EU-Cardioprotection CA16225)
HORIZON EUROPE Framework Programme (EU-Cardioprotection CA16225)
EFSD (2018)
Boehringer Ingelheim Stiftung (research grant)
National Natural Science Foundation of China (82400401)
- License Information
-
More Information
Article History
Received: 28 April 2023
Revised: 12 June 2025
Accepted: 12 June 2025
First Online: 19 June 2025
Declarations
:
: PF is the founder and CEO of Pharmahungary Group, a group of R&D companies . All other authors report no conflict of interest.
